Metformin vs Ozempic (Semaglutide): Uses, Weight, Heart & Kidney Benefits, Safety

Quick Answer: Metformin is an oral biguanide labeled to improve blood sugar control in adults and children 10 and older with type 2 diabetes. Ozempic (semaglutide) is a once-weekly GLP-1 receptor agonist injection labeled for blood sugar control in adults with type 2 diabetes, to reduce major cardiovascular events in those with established heart disease, and to reduce kidney decline and cardiovascular death in those with chronic kidney disease. The ADA Standards of Care 2025 recommend choosing therapy based on individual factors, and favor GLP-1 receptor agonists or SGLT2 inhibitors with proven benefit for people with heart or kidney disease, regardless of metformin use. Ozempic typically produces more weight loss; metformin’s weight effect is modest. The two are frequently combined.

Metformin vs Ozempic at a Glance

Feature	Metformin	Ozempic (semaglutide)
Form	Tablet (immediate or extended release)	Injection under the skin, once weekly
FDA-labeled uses	Blood sugar control in type 2 diabetes (age 10+)	Blood sugar control in adult type 2 diabetes; reduce cardiovascular events (with heart disease); reduce kidney decline (with CKD)
How it works	Lowers liver glucose production; improves insulin sensitivity	Mimics GLP-1: boosts glucose-dependent insulin, lowers glucagon, slows stomach emptying, reduces appetite
Label dosing	Start 500 mg twice daily or 850 mg daily with meals; max 2,550 mg/day	Start 0.25 mg weekly for 4 weeks, then increase stepwise
Weight	Modest loss or weight neutral	Greater weight loss on average
Common side effects	Diarrhea, nausea, stomach upset; vitamin B12 lowering	Nausea, vomiting, diarrhea, constipation
Boxed warning	Lactic acidosis (rare)	Thyroid C-cell tumors (in rodents)
Low blood sugar alone	Uncommon	Uncommon; higher with insulin or sulfonylureas

Doses above are from the current U.S. Drug Facts or prescribing labels listed in Sources. Always follow the label on the package you buy, because store brands and formulations differ.

How Each Drug Works

Metformin has been a foundation of type 2 diabetes treatment for decades. It reduces the amount of glucose the liver releases and improves how the body responds to insulin. It does not stimulate insulin release, which is why it rarely causes low blood sugar when used alone.

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a gut hormone. It increases insulin release only when blood sugar is high, reduces glucagon, slows stomach emptying and acts on appetite centers in the brain. Those effects lower blood sugar and reduce food intake, leading to weight loss. The same molecule at higher doses is sold as Wegovy for chronic weight management; Ozempic is the diabetes-labeled product.

What Each Is FDA-Labeled For

The metformin label lists use as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes.

The Ozempic label lists three uses in adults with type 2 diabetes: improving glycemic control alongside diet and exercise; reducing the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in those with established cardiovascular disease; and reducing the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in those with chronic kidney disease. Ozempic is not labeled for type 1 diabetes or for weight loss alone.

What Diabetes Guidelines Say

The American Diabetes Association’s Standards of Care in Diabetes—2025 (Section 9, Pharmacologic Approaches to Glycemic Treatment) emphasizes person-centered choices that consider heart and kidney disease, weight goals, risk of low blood sugar, side effects and access. For adults with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure or chronic kidney disease, the ADA recommends a GLP-1 receptor agonist and/or SGLT2 inhibitor with demonstrated benefit as part of the regimen, independent of A1C and independent of metformin use. Metformin remains an effective option for many people, especially when such conditions are absent. In short: it is not always a choice between the two.

Weight Effects

Weight loss is the most-searched difference. Metformin is generally weight neutral or associated with modest loss. In the Diabetes Prevention Program (Knowler, NEJM, 2002), which studied adults with prediabetes rather than diabetes, metformin 850 mg twice daily reduced the incidence of diabetes by 31% compared with placebo, while an intensive lifestyle program reduced it by 58%.

Semaglutide generally produces larger weight loss. The best-known data come from the STEP 1 trial (Wilding, NEJM, 2021) of semaglutide 2.4 mg weekly (the Wegovy dose) in adults with obesity without diabetes: mean body weight fell 14.9% over 68 weeks vs 2.4% with placebo, alongside lifestyle intervention. Ozempic’s doses are lower and people with diabetes typically lose less weight than people without diabetes, so STEP 1 results should not be applied directly to Ozempic.

Dosing

Per the metformin label, adults usually start with 500 mg twice daily or 850 mg once daily with meals, increasing gradually (by 500 mg weekly or 850 mg every two weeks) to a maximum of 2,550 mg per day. Taking it with food and increasing slowly reduces stomach side effects; extended-release versions are often better tolerated.

Per the Ozempic label, treatment starts at 0.25 mg once weekly for 4 weeks (a starter dose to improve tolerability, not for blood sugar control) and then increases stepwise to maintenance doses as needed. It is injected under the skin of the abdomen, thigh or upper arm on the same day each week.

Side Effects and Warnings

Metformin

Digestive effects: diarrhea, nausea and stomach upset are common, especially at the start.
Lactic acidosis: a rare but serious boxed warning; risk rises with kidney impairment, liver disease, heavy alcohol use, severe illness and certain imaging dyes.
Kidney function: the label says not to use metformin if eGFR is below 30, not to start it if eGFR is 30 to 45, and to reassess if eGFR falls below 45.
Vitamin B12: the label says metformin may lower B12 levels and recommends periodic checks.
Imaging: it may need to be paused around procedures using iodinated contrast.

Ozempic

Digestive effects: nausea, vomiting, diarrhea, abdominal pain and constipation are the most common, mostly during dose increases.
Thyroid C-cell tumors: a boxed warning based on rodent studies; Ozempic is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
Other warnings: pancreatitis, gallbladder disease, low blood sugar when combined with insulin or sulfonylureas, acute kidney injury from dehydration, diabetic retinopathy complications in people with existing retinopathy, and pulmonary aspiration during anesthesia.

Taking Them Together

Metformin and a GLP-1 receptor agonist are commonly prescribed together, because they work by different mechanisms. Both can cause stomach side effects, so prescribers often adjust timing and doses. If you are on either, do not stop or change doses without talking to your clinician.

What About Prediabetes or Weight Loss Without Diabetes?

Neither Ozempic nor metformin is FDA-labeled for weight loss in people without diabetes. Semaglutide for chronic weight management is sold as Wegovy, which has its own label. Metformin is sometimes prescribed off-label for prediabetes, supported by the Diabetes Prevention Program, but lifestyle change was more effective in that trial. See our semaglutide vs tirzepatide comparison for the weight-management drugs.

Questions to Ask Your Clinician

Do I have heart disease, heart failure or kidney disease that would favor a GLP-1 receptor agonist or SGLT2 inhibitor?
How important is weight loss for my health goals?
Can I manage weekly injections, and how will we handle side effects during dose increases?
Does my kidney function allow metformin, and should my vitamin B12 be checked?
Does my insurance or plan cover each option? (Coverage varies widely.)

When to Talk to Your Doctor or Pharmacist

Seek emergency care for severe, persistent abdominal pain (possible pancreatitis), signs of lactic acidosis (unusual muscle pain, trouble breathing, extreme weakness, stomach pain with nausea), a lump or swelling in the neck, trouble swallowing, or symptoms of very low blood sugar. Contact your clinician about persistent vomiting or diarrhea, which can cause dehydration and kidney problems, and before any surgery or imaging with contrast dye.

Frequently Asked Questions

Is Ozempic better than metformin?

It depends on the person. Ozempic has labeled cardiovascular and kidney benefits for certain adults with type 2 diabetes and typically causes more weight loss. Metformin is an established oral option. The ADA recommends individualized choices and often both are used.

Can you take metformin and Ozempic together?

Yes, they are commonly prescribed together for type 2 diabetes because they work differently. Your clinician manages the doses.

Does metformin cause weight loss like Ozempic?

Metformin is generally weight neutral or causes modest loss. Semaglutide produces larger average weight loss in trials.

Is Ozempic approved for weight loss?

No. Ozempic is labeled for type 2 diabetes. Semaglutide for chronic weight management is sold as Wegovy.

Do I have to take metformin before Ozempic?

Not necessarily. ADA 2025 guidance recommends GLP-1 receptor agonists or SGLT2 inhibitors for people with heart or kidney disease regardless of metformin use.

Does metformin lower vitamin B12?

Yes. The label says metformin may lower vitamin B12 and recommends periodic monitoring.

Sources

Medical disclaimer: This article is for educational purposes and does not replace medical advice. Consult a licensed healthcare provider before starting any supplement, medication, or treatment — particularly if you are pregnant, breastfeeding, taking other medications, or have a diagnosed medical condition.